-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CAR-T Cells vs. Allogeneic HSCT for Poor Risk ALL

Program: Education Program
Session: Pediatric Hematological Malignancies: CARs for Kids
Hematology Disease Topics & Pathways:
Leukemia, ALL, Biological, Diseases, Therapies, CAR-Ts, Pediatric, Lymphoid Malignancies, Study Population, Clinically relevant
Monday, December 7, 2020, 11:25 AM-11:30 AM

Shannon L. Maude, MD, PhD

Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA

Disclosures: Maude: Kite Pharma: Consultancy; Novartis Pharmaceuticals: Consultancy.

OffLabel Disclosure: Off-label and investigational use of CD19 CAR T cell products will be discussed.

Previous Presentation | Next Presentation >>